公开(公告)号：EP2497492B1

公开(公告)日：2018-08-08

申请号：EP12163377.0

申请日：2005-06-01

申请人： Icahn School of Medicine at Mount Sinai ,  The United States of America as represented by the Secretary of Agriculture ,  St. Jude Children's Research Hospital

发明人： Palese, Peter ,  Garcia-Sastre, Adolfo ,  Webby, Richard, J ,  Richt, Juergen, A. ,  Webster, Robert ,  Lager, Kelly, M.

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  C12N15/64 ,  C12N5/00 ,  A61K39/116

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS 1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

公开(公告)号：EP3332803A1

公开(公告)日：2018-06-13

申请号：EP17209515.0

申请日：2005-06-01

申请人： Icahn School of Medicine at Mount Sinai ,  The United States of America as represented by the Secretary of Agriculture ,  St. Jude Children's Research Hospital

发明人： Palese, Peter ,  Garcia-Sastre, Adolfo ,  Webby, Richard J. ,  Richt, Juergen A. ,  Webster, Robert ,  Lager, Kelly M.

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  C12N15/64 ,  C12N5/00 ,  A61K39/116

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

摘要： This invention provides a genetically engineered attenuated swine influenza virus, wherein the virus comprises a swine influenza virus NS1 gene with a mutation that results in a swine influenza virus NS1 protein carrying a deletion within its carboxy-terminus. The invention also provides a composition comprising said genetically engineered attenuated swine influenza virus. Additionally, a genetically engineered swine influenza virus is provided for immunization of a pig or prevention of a disease or symptom associated with swine influenza virus. The invention also provides a cultured cell or an embryonated egg containing said genetically engineered attenuated swine influenza virus and a method for production of an immunogenic composition or a pharmaceutical composition.

公开(公告)号：EP2139515B1

公开(公告)日：2018-06-13

申请号：EP08799746.6

申请日：2008-03-31

申请人： The Research Foundation of the State University of New York

发明人： WIMMER, Eckard ,  SKIENA, Steve ,  MUELLER, Steffen ,  FUTCHER, Bruce ,  PAPAMICHAIL, Dimitris ,  COLEMAN, John, Robert ,  CELLO, Jeronimo

IPC分类号： A61K39/13

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/13 ,  A61K39/145 ,  A61K2039/5254 ,  C07K14/005 ,  C12N2720/12361 ,  C12N2740/15061 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16162 ,  C12N2770/20061 ,  C12N2770/24161 ,  C12N2770/32061 ,  C12N2770/32621 ,  C12N2770/32634 ,  C12N2770/32661 ,  C12N2770/32662 ,  C12N2770/32671 ,  C12N2770/32721 ,  C12N2770/32761 ,  C12N2770/32762 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/466

摘要： This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

公开(公告)号：EP1773384B1

公开(公告)日：2015-08-12

申请号：EP05856778.5

申请日：2005-06-01

申请人： Icahn School of Medicine at Mount Sinai ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL ,  The United States of America as represented by the Secretary of Agriculture

发明人： GARCIA-SASTRE, Adolfo ,  PALESE, Peter ,  LAGER, Kelly, M. ,  WEBSTER, Robert ,  RICHT, Juergen, A. ,  WEBBY, Richard, J.

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  C12N15/64 ,  C12N5/00 ,  A61K39/116

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

公开(公告)号：EP1420065A1

公开(公告)日：2004-05-19

申请号：EP02746156.5

申请日：2002-08-01

申请人： Anges MG Inc.

发明人： KANEDA, Yasufumi, c/o AnGes MG, Inc.

IPC分类号： C12N7/02 ,  C12N15/90 ,  A61K35/76 ,  A61K48/00

CPC分类号： C12N7/00 ,  A61K35/76 ,  A61K48/0016 ,  C12N15/88 ,  C12N2760/16051 ,  C12N2760/16061 ,  C12N2760/16063 ,  C12N2760/18851 ,  C12N2760/18861 ,  C12N2760/18863 ,  C12N2770/36151

摘要： The present invention relates to an advantageous process for industrially producing an inactivated virus (e.g., HVJ, etc.) envelope. To solve the problem, the present invention provides a process for treating a virus with an alkylating agent to produce an inactivated virus envelope. A vector for introducing a biological macromolecule, such as a gene or the like, which is prepared from the inactivated HVJ envelope of the present invention, can be used for genetic function analysis or gene therapy. Specifically, the present invention comprises the steps of (a) inactivating a virus with an alkylating agent, (b) obtaining a condensate solution of the virus or the inactivated virus, and (c) purifying the virus or the inactivated virus by column chromatography and then ultrafiltration. The present invention also provides a composition and pharmaceutical agent which utilize an envelope obtained by the process of the present invention.

摘要翻译： 本发明涉及工业生产灭活病毒（例如，HVJ等）包膜的有利方法。 为了解决该问题，本发明提供了用烷基化剂处理病毒以产生灭活的病毒包膜的方法。 用于引入由本发明的灭活HVJ包膜制备的生物大分子如基因等的载体可用于遗传功能分析或基因治疗。 具体而言，本发明包括以下步骤：（a）用烷基化剂灭活病毒，（b）获得病毒或灭活病毒的冷凝液，（c）通过柱色谱纯化病毒或灭活病毒， 然后超滤。 本发明还提供利用通过本发明的方法获得的包膜的组合物和药剂。

公开(公告)号：EP1075524A2

公开(公告)日：2001-02-14

申请号：EP99919444.2

申请日：1999-05-06

申请人： ISIS INNOVATION LIMITED

发明人： BROWNLEE, George, Gow ,  FODOR, Ervin ,  PALESE, PeterMount Sinai School of Medicine ,  GARC A-SASTRE, AdolfoMount Sinai School of Medic.

IPC分类号： C12N15/44 ,  C12N7/01 ,  C12N15/86 ,  A61K39/145

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/16022 ,  C12N2760/16043 ,  C12N2760/16061 ,  C12N2760/16134

摘要： An attenuated influenza virus carrying a genomic nucleic acid segment which comprises 5' and 3' non-coding regions providing a mutated duplex region of an influenza virus RNA genomic segment operably-linked to a protein coding sequence for an influenza viral protein or a functional modification thereof, wherein said duplex region has at least one base-pair substitution such that expression of said protein-coding sequence in cells infected by said virus is reduced to give an attenuated phenotype. The attenuated influenza virus can be used in a vaccine.

公开(公告)号：EP0989860A1

公开(公告)日：2000-04-05

申请号：EP99917408.9

申请日：1999-04-12

申请人： NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.

发明人： PLAUT, Andrew, G. ,  QIU, Jiazhou

IPC分类号： A61K38/40 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  C07K14/79

CPC分类号： C12N7/00 ,  A61K38/00 ,  A61K38/1709 ,  A61K39/102 ,  A61K2039/541 ,  C07K14/79 ,  C12N2760/16061

摘要： A method for substantially reducing the pathogenicity of an infectious agent, without killing the infectious agent, by removing or degrading a surface protein of the infectious agent, by contacting the infectious agent with substantially pure, non-pasteurized, naturally occurring lactoferrin under conditions sufficient to remove or degrade the protein, is disclosed.

公开(公告)号：EP2864471B1

公开(公告)日：2017-03-08

申请号：EP13733496.7

申请日：2013-06-20

申请人： F. Hoffmann-La Roche AG

发明人： SHIRATORI, Masaru, Ken ,  KISS, Robert, David ,  PRASHAD, Hardayal ,  IVERSON, Raquel ,  BOURRET, Justin ,  KIM, Michael ,  CHARANIYA, Salim

IPC分类号： C12N5/00

CPC分类号： C12N1/36 ,  C12N7/00 ,  C12N2750/14061 ,  C12N2760/12061 ,  C12N2760/16061 ,  C12N2760/18061 ,  C12N2760/20061 ,  C12N2770/16061 ,  C12N2770/32061 ,  C12N2770/36061

摘要： The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.

公开(公告)号：EP2969005A1

公开(公告)日：2016-01-20

申请号：EP14763039.6

申请日：2014-03-15

申请人： The Research Foundation for The State University of New York

发明人： MUELLER, Steffen ,  WIMMER, Eckard ,  FUTCHER, Bruce ,  SKIENA, Steven ,  YANG, Chen

IPC分类号： A61P31/16 ,  C12N7/04

CPC分类号： C12N7/00 ,  A61K39/145 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16134 ,  C12N2760/16162

摘要： This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.

公开(公告)号：EP2497492A1

公开(公告)日：2012-09-12

申请号：EP12163377.0

申请日：2005-06-01

申请人： Mount Sinai School of Medicine ,  The United States of America as represented by the secretary of Agriculture ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： Palese, Peter ,  Garcia-Sastre, Adolfo ,  Webby, Richard, J ,  Richt, Juergen, A. ,  Webster, Robert ,  Lager, Kelly, M.

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  C12N15/64 ,  C12N5/00 ,  A61K39/116

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

摘要： The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS 1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

摘要翻译： 本发明一般涉及具有拮抗细胞干扰素（IFN）应答能力受损的减毒猪流感病毒，以及在疫苗和药物制剂中使用这种减毒病毒。 特别地，本发明涉及具有修饰猪NS1基因的减毒猪流感病毒，其减少或消除NS1基因产物拮抗细胞IFN应答的能力。 这些病毒在体内复制，但表现出降低的复制，毒力和增加的衰减，因此非常适合用于活病毒疫苗和药物制剂。